Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) Return on Equity (2020 - 2025)

Insight Molecular Diagnostics' Return on Equity history spans 6 years, with the latest figure at 15.14% for Q3 2025.

  • For Q3 2025, Return on Equity rose 1683.0% year-over-year to 15.14%; the TTM value through Sep 2025 reached 15.14%, up 1683.0%, while the annual FY2024 figure was 14.9%, 1479.0% down from the prior year.
  • Return on Equity for Q3 2025 was 15.14% at Insight Molecular Diagnostics, up from 11.27% in the prior quarter.
  • Across five years, Return on Equity topped out at 56.98% in Q1 2025 and bottomed at 11.27% in Q2 2025.
  • The 5-year median for Return on Equity is 0.8% (2024), against an average of 5.07%.
  • The largest YoY upside for Return on Equity was 5755bps in 2025 against a maximum downside of -1047bps in 2025.
  • A 5-year view of Return on Equity shows it stood at 0.82% in 2021, then dropped by -19bps to 0.98% in 2022, then skyrocketed by 89bps to 0.1% in 2023, then soared by 46074bps to 47.52% in 2024, then crashed by -68bps to 15.14% in 2025.
  • Per Business Quant, the three most recent readings for IMDX's Return on Equity are 15.14% (Q3 2025), 11.27% (Q2 2025), and 56.98% (Q1 2025).